Page 3 - Johnc Klock News Today

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) issued an update on its FY 2023 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $1.80-$2.05 for the period, compared to the consensus estimate of $0.95. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate of $2.46 […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) had its target price raised by Robert W. Baird from $112.00 to $127.00 in a report issued on Thursday morning, The Fly reports. A number of other brokerages have also recently issued reports on BMRN. StockNews.com began coverage on shares of BioMarin Pharmaceutical in a research note on Thursday, […]

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 6,430,000 shares, a growth of 8.2% from the March 31st total of 5,940,000 shares. Approximately 3.5% of the company’s shares are sold short. Based […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) issued an update on its FY 2023 earnings guidance on Thursday morning. The company provided earnings per share guidance of $1.80-$2.05 for the period, compared to the consensus earnings per share estimate of $0.95. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) issued an update on its FY 2023 earnings guidance on Thursday morning. The company provided earnings per share guidance of $1.80-$2.05 for the period, compared to the consensus earnings per share estimate of $0.95. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate […]

Should You Buy or Sell BioMarin Pharmaceutical Stock? Get The Latest BMRN Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Friday. Other research analysts also recently issued research reports about the company. Robert W. Baird boosted their target price on BioMarin Pharmaceutical from $112.00 to $127.00 in a research note […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) had its price objective reduced by Guggenheim from $125.00 to $120.00 in a report released on Thursday, The Fly reports. A number of other brokerages have also recently commented on BMRN. Sanford C. Bernstein assumed coverage on BioMarin Pharmaceutical in a research note on Tuesday, March 21st. They set […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided EPS guidance of $1.80-2.05 for the period, compared to the consensus EPS estimate of $1.98. The company issued revenue guidance of $2.375-2.500 billion, compared to the consensus revenue estimate of $2.46 billion. Wall Street Analyst Weigh In Several equities […]

Waycross Partners LLC increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 9.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,000 shares of the biotechnology company’s stock after purchasing an additional 600 shares during the period. Waycross Partners LLC’s holdings in BioMarin […]